G Protein News and Research

RSS

New U.S. patent covers key element of Xencor's Xtend half-life prolongation technology

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.

7 Jan 2012

Silence completes siRNA research work with AstraZeneca, MedImmune

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca and its biologics arm, MedImmune.

7 Jan 2012

Poor nutrition in the womb can increase risk of type 2 diabetes in later life

Researchers funded by the Biotechnology and Biological Sciences Research Council have shown one way in which poor nutrition in the womb can put a person at greater risk of developing type 2 diabetes and other age-related diseases in later life.

7 Jan 2012

Researchers crack structure and function of malarial protein

A biology lab at Washington University has just cracked the structure and function of a protein that plays a key role in the life of a parasite that killed 655,000 people in 2010.

7 Jan 2012

Studies identify genes and small molecules against protein conformational diseases

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.

7 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

AHA honors Rice University professor with Established Investigator Award

Rice University's Jane Grande-Allen, one of the world's foremost experts on the biomechanics of heart-valve tissue, has won an Established Investigator Award from the American Heart Association.

6 Jan 2012

Scripps professor receives pair of notable grants to study kinesin

Sathyanaryanan Puthanveettil, an assistant professor on the Florida campus of The Scripps Research Institute, has been awarded a pair of notable grants to study a critical component of long-term memory formation.

6 Jan 2012

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.

6 Jan 2012

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

6 Jan 2012

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

New laboratory approach could aid brain recovery

In humans, active periods of the debilitating disease Multiple Sclerosis (MS) can last for mere minutes or extend to weeks at a time. They're caused by lesions in the brain that develop, partly heal, and then recur. Research into a cure has been difficult, because to date scientists have not been able to replicate these brain recurring symptoms in laboratory mice. That's frustrating because these lab animals, known as animal "models," are the primary tool for research into the mechanisms and potential treatments for MS.

6 Jan 2012

Researchers identify potential target for schistosomiasis vaccine

In the complicated life cycle of ancient flatworms that cause schistosomiasis, Case Western Reserve University researchers have identified a gene activator crucial to development of the parasites within humans - a potential target for a vaccine.

6 Jan 2012

Baxter commences BAX 855 Phase I trial in hemophilia A

Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.

From Baxter International Inc. 5 Jan 2012

2012 ‘Best Diets’ rankings

Those aspiring to lose weight and eat healthy this New Year may benefit from the U.S. News & World Report's 2012 Best Diets rankings. Each year, U.S. News accumulates data from scientific journals, government reports, and solicits input from 22 experts in food science and nutrition, to come up for its rankings.

5 Jan 2012

Repeated episodes of depression contribute to inflammation

An important ongoing debate in the field of psychiatry is whether inflammation in the body is a consequence of or contributor to major depression. A new study in Biological Psychiatry has attempted to resolve the issue.

5 Jan 2012

Vitamin D may stop conferring cardiovascular benefits: Study

New research by Johns Hopkins scientists suggests that vitamin D, long known to be important for bone health and in recent years also for heart protection, may stop conferring cardiovascular benefits and could actually cause harm as levels in the blood rise above the low end of what is considered normal.

5 Jan 2012

Novel vaccine combinations can protect against infection by SIV

Results from a recent study show that novel vaccine combinations can provide partial protection against infection by Simian Immunodeficiency Virus (SIV) in rhesus monkeys.

5 Jan 2012

Working Group recommends use of biomarkers in AD clinical trials

A group of thought leaders in Alzheimer's disease says the science is solid and the time has come for more widespread use of biomarkers in Alzheimer disease (AD) clinical trials, to speed the identification of effective disease-modifying treatments for this incurable disorder.

5 Jan 2012

RGS9-2 gene plays a role in regulating body weight

Abraham Kovoor was studying a brain protein, called RGS9 2, that he had previously related to the involuntary, random and repetitive body movements that are side effects of drugs used to treat Parkinson's disease and schizophrenia.

5 Jan 2012